Aptol Pharma is a biotechnology platform company which aims to develop first-in-class functional cures for a broad range of autoimmune diseases via our proprietary peptide-nanoparticle technology.
Four founders of the company together with our BoD strive to make our first asset APT001 for rheumatoid arthritis Phase 1 ready in 2025:
Founders:
Kira Astakhova: Ass. Professor at DTU, Expert in the aptamer technology development
Mads Clausen - Professor at DTU and expert in bioorganic chemistry
Tue Wenzel Kragstrup - Rheumatology specialist, Clinician
Mark Daniel Zalomajev - marketing and business developer
BoD:
Anders Dyhr Dombernowsky-Toft (Exec. Chairman)
Nicolai Wagtmann"
Company Details
- Employees
- 6
- Founded
- -
- Address
- Thad Jones Vej 6 St Th, Copenhagen,sealand 2450,denmark
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.aptolpharma.com/
- HQ
- Copenhagen, Sealand
Aptol Pharma Questions
Aptol Pharma's website is https://www.aptolpharma.com/
Aptol Pharma's LinkedIn profile is https://dk.linkedin.com/company/aptolpharma
Aptol Pharma has
6 employees.
View email and phone details for 6
employees at Aptol Pharma.
Aptol Pharma's industry is
Biotechnology Research
Aptol Pharma's top competitors are
2a Pharma,
Imp Scandinavia,
Cessatech A/s,
Cytoki Pharma,
Innels,
Embark Laboratories,
Yeti Foods,
Macure Pharma,
Sunstone Life Science Ventures,
Nmd Pharma A/s.
Aptol Pharma's categories are Biotechnology Research
Aptol Pharma's founding year is 2018
